General Clinical Chemistry Analyzers and Accessories
Abcam TW-37, 100MG
MW 573.7 Da, Purity >98%. Small-molecule inhibitor of BCL-2 (Ki = 0.29 μM). Inhibits multiple BCL-2 family members including BCL-XL (Ki = 1.11 μM) and MCL-1 (Ki= 0.26 μM). Binds to the BCL-2 homology domain 3 (BH3) groove of BCL-2. Significant anti-proliferative and pro-apoptotic activity in lymphoma cells.
The product is subject to the following: Abcam Restricted Use Statement
Abcam AZ-20, 25MG
MW 412.5 Da. Potent and selective ATR kinase inhibitor (IC₅₀ = 5 nM in vitro; IC₅₀ = 50 nM in carcinoma cell lines). Selective versus mTOR (8-fold). Displayed selectivity versus a panel of 442 kinases.Inhibits LoVo colorectal adenocarcinoma tumor cell growth.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Ryuvidine, 25MG
MW 284.3 Da, Purity >98%. Inhibits (IC₅₀ = 500 nM) KMT5A / SETD8 / Pr-SET7 and suppresses H4JK20 monomethylation in vitro. Weakly active against Cdk4 (IC₅₀ = 6 μM). Induces S-phase accumulation in HEK-293 cells. Cytotoxic towards a number of human cancer cell lines. May induce the DNA damage response.
The product is subject to the following: Abcam Restricted Use Statement
Abcam IO x 2, HIF-1alpha prolyl hydro x ylase-2 (PHD2) inhibitor, 5MG
MW 352.3 Da, Purity >98%. Potent, cell-permeable, selective HIF-1α prolyl hydroxylase-2 (PHD2) inhibitor (IC₅₀ = 21 nM). Displays over 100-fold selectivity for PHD2 over factor inhibiting HIF-1 (FIH-1) and histone demethylases JMJD2A, JMJD2C, JMJD2E and JMJD3.
The product is subject to the following: Abcam Restricted Use Statement
Abcam SGI1776, 10MG
MW 405.4 Da, Purity >99%. Novel ATP competitive inhibitor of Pim1 with IC50 of 7 nM, 50- and 10-fold selective versus Pim2 and Pim3. Preliminary results from studies treating prostate cancer cells.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Ledipasvir, 5A of hepatitis C virus inhibitor, 5MG
MW 889 Da. Ledipasvir is an inhibitor of non-structural protein 5A of hepatitis C virus. It has potent effects against genotypes 1a, 1b, 4a, and 5a in vitro, but has lower activity against genotypes 2a and 3a. Ledipasvir can have additive to synergistic in vitro antiviral activity when combined with other agents.
The product is subject to the following: Abcam Restricted Use Statement
Abcam CUR 61414, Hedgehog signaling pathway antagonist, 25MG
MW 550.7 Da, Purity >98%. Novel, cell permeable Hedgehog signaling pathway antagonist (IC₅₀ = 100-200 nM). Selectively binds to smoothened (Smo) (Ki = 44 nM). Blocks the formation of and induces the regression of basaloid lesions in skin punches and shrinks UV-induced basaloid lesions in adult mouse skin. Inhibits proliferation and induces apoptosis in tumor cells without affecting non-tumor cells.
The product is subject to the following: Abcam Restricted Use Statement
Abcam D-Gluconic acid, methyl ester, 50MG
MW 210.18 g/mol. Membrane permeant analog of D-gluconic acid. Useful as a component of cell culture media; enzymatic degradation of xylan and glucomannan; various pharmaceutical preparations; as well as an intermediate in carbohydrate based synthetic preparations of sugar derivatives.
The product is subject to the following: Abcam Restricted Use Statement
Abcam LRRK2-IN-1, LRRK2 inhibitor, 50MG
MW 570.7 Da. Potent and selective inhibitor of the Parkinson's disease kinase LRRK2. Benzodiazepine based derivative. Inhibits both G2019S mutant and wild-type LRRK2 kinase activity (IC₅₀ values are 6 and 13 nM respectively). Causes dephosphorylation, ubiquitination and degradation of LRRK2. Inhibits IFN-γ-induced monocyte maturation in vitro.
The product is subject to the following: Abcam Restricted Use Statement
